A review of insulin lispro for the treatment of patients with type 2 diabetes mellitus

A critical aspect of the treatment of most patients with type 2 diabetes mellitus (T2DM) is the initiation (and subsequent intensification) of insulin therapy when lifestyle interventions and oral anti-hyperglycaemic drugs fail to maintain or improve glycaemic control. There are several insulin trea...

Full description

Bibliographic Details
Main Authors: Marina V. Shestakova, Svetlana V. Elizarova, Abdul Jabbar
Format: Article
Language:English
Published: Endocrinology Research Centre 2016-07-01
Series:Сахарный диабет
Subjects:
Online Access:https://www.dia-endojournals.ru/jour/article/view/7595
_version_ 1826588112935976960
author Marina V. Shestakova
Svetlana V. Elizarova
Abdul Jabbar
author_facet Marina V. Shestakova
Svetlana V. Elizarova
Abdul Jabbar
author_sort Marina V. Shestakova
collection DOAJ
description A critical aspect of the treatment of most patients with type 2 diabetes mellitus (T2DM) is the initiation (and subsequent intensification) of insulin therapy when lifestyle interventions and oral anti-hyperglycaemic drugs fail to maintain or improve glycaemic control. There are several insulin treatment options available, including basal insulin, basal-bolus insulin and premixed insulin. Each of these options has advantages and disadvantages. The insulin lispro premixed insulin analogues, mix 25 (25% insulin lisproand 75% insulin lispro protamine suspension) and mix 50 (50% insulin lispro and 50% insulin lispro protamine suspension), which include intermediate- and rapid-acting components, were recently added to Russia’s national drug reimbursement program, increasing the treatment options for patients with T2DM. The aim of this review is to provide Russian physicians with current information on the efficacy and safety of insulin lispro, with a focus on insulin lispro mixtures, for the treatment of T2DM.
first_indexed 2024-03-08T15:20:16Z
format Article
id doaj.art-72ce33b77d6449dd98806bc75c8fa576
institution Directory Open Access Journal
issn 2072-0351
2072-0378
language English
last_indexed 2025-03-14T16:36:09Z
publishDate 2016-07-01
publisher Endocrinology Research Centre
record_format Article
series Сахарный диабет
spelling doaj.art-72ce33b77d6449dd98806bc75c8fa5762025-02-21T09:29:33ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782016-07-0119324225010.14341/DM2003429-347365A review of insulin lispro for the treatment of patients with type 2 diabetes mellitusMarina V. Shestakova0Svetlana V. Elizarova1Abdul Jabbar2Endocrinology Research Centre; I.M.Sechenov First Moscow State Medical UniversityEli Lilly Vostok S.A.Eli Lilly S.A.A critical aspect of the treatment of most patients with type 2 diabetes mellitus (T2DM) is the initiation (and subsequent intensification) of insulin therapy when lifestyle interventions and oral anti-hyperglycaemic drugs fail to maintain or improve glycaemic control. There are several insulin treatment options available, including basal insulin, basal-bolus insulin and premixed insulin. Each of these options has advantages and disadvantages. The insulin lispro premixed insulin analogues, mix 25 (25% insulin lisproand 75% insulin lispro protamine suspension) and mix 50 (50% insulin lispro and 50% insulin lispro protamine suspension), which include intermediate- and rapid-acting components, were recently added to Russia’s national drug reimbursement program, increasing the treatment options for patients with T2DM. The aim of this review is to provide Russian physicians with current information on the efficacy and safety of insulin lispro, with a focus on insulin lispro mixtures, for the treatment of T2DM.https://www.dia-endojournals.ru/jour/article/view/7595type 2 diabetes mellitushumaloginsulin lispropremixed insulin analoginitiationintensificationglycated hemoglobinefficacysafety
spellingShingle Marina V. Shestakova
Svetlana V. Elizarova
Abdul Jabbar
A review of insulin lispro for the treatment of patients with type 2 diabetes mellitus
Сахарный диабет
type 2 diabetes mellitus
humalog
insulin lispro
premixed insulin analog
initiation
intensification
glycated hemoglobin
efficacy
safety
title A review of insulin lispro for the treatment of patients with type 2 diabetes mellitus
title_full A review of insulin lispro for the treatment of patients with type 2 diabetes mellitus
title_fullStr A review of insulin lispro for the treatment of patients with type 2 diabetes mellitus
title_full_unstemmed A review of insulin lispro for the treatment of patients with type 2 diabetes mellitus
title_short A review of insulin lispro for the treatment of patients with type 2 diabetes mellitus
title_sort review of insulin lispro for the treatment of patients with type 2 diabetes mellitus
topic type 2 diabetes mellitus
humalog
insulin lispro
premixed insulin analog
initiation
intensification
glycated hemoglobin
efficacy
safety
url https://www.dia-endojournals.ru/jour/article/view/7595
work_keys_str_mv AT marinavshestakova areviewofinsulinlisproforthetreatmentofpatientswithtype2diabetesmellitus
AT svetlanavelizarova areviewofinsulinlisproforthetreatmentofpatientswithtype2diabetesmellitus
AT abduljabbar areviewofinsulinlisproforthetreatmentofpatientswithtype2diabetesmellitus
AT marinavshestakova reviewofinsulinlisproforthetreatmentofpatientswithtype2diabetesmellitus
AT svetlanavelizarova reviewofinsulinlisproforthetreatmentofpatientswithtype2diabetesmellitus
AT abduljabbar reviewofinsulinlisproforthetreatmentofpatientswithtype2diabetesmellitus